Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Seagen Inc.

< Previous 1 2 Next >
PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) Significantly Improve Overall Survival and Progression-Free Survival in Patients With Previously Untreated Advanced Bladder Cancer in Pivotal Phase 3 EV-302 Trial
From Seagen Inc.
Via Business Wire
Tickers SGEN
Seagen and Genmab Announce TIVDAK® (tisotumab vedotin-tftv) Improved Overall Survival in Patients With Recurrent or Metastatic Cervical Cancer Compared With Chemotherapy Alone
From Seagen Inc.
Via Business Wire
Tickers GMAB SGEN
Seagen Phase 3 Trial of TUKYSA® (tucatinib) in Combination with Antibody-Drug Conjugate ado-trastuzumab emtansine Meets Primary Endpoint of Progression-Free Survival in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer
From Seagen Inc.
Via Business Wire
Tickers SGEN
Seagen Second Quarter 2023 Financial Results Demonstrate Exceptional Commercial Performance Driving Record Product Sales with Strong Growth and Momentum
From Seagen Inc.
Via Business Wire
Tickers SGEN
Seagen to Report Second Quarter 2023 Financial Results on August 2, 2023
From Seagen Inc.
Via Business Wire
Tickers SGEN
Phase 3 Trial of ADCETRIS® (brentuximab vedotin) with Modified Chemo Regimen Shows Non-Inferiority with Unprecedented 3-Year Progression Free Survival of 94.9% vs Less Tolerable International Standard of Care in Advanced Classical Hodgkin Lymphoma
From Seagen Inc.
Via Business Wire
Tickers SGEN
Six-Year Overall Survival Results Added to U.S. Prescribing Information for ADCETRIS® (brentuximab vedotin) as First-Line Treatment for Advanced Hodgkin Lymphoma
From Seagen Inc.
Via Business Wire
Tickers SGEN
Seagen Announces ADCETRIS® (brentuximab vedotin) Plus Novel Immunotherapy Combination Delivers 98% Overall Response Rate and 93% Complete Response Rate in Patients with Early-Stage Classical Hodgkin Lymphoma (cHL)
From Seagen Inc.
Via Business Wire
Tickers SGEN
Seagen Stockholders Approve Acquisition by Pfizer
From Seagen Inc.
Via Business Wire
Tickers SGEN
Seagen Reports First Quarter 2023 Financial Results
From Seagen Inc.
Via Business Wire
Tickers SGEN
Seagen to Highlight Data From Oncology Portfolio and Pipeline at the 2023 American Society of Clinical Oncology Annual Meeting
From Seagen Inc.
Via Business Wire
Tickers SGEN
Seagen to Report First Quarter 2023 Financial Results on April 27, 2023
From Seagen Inc.
Via Business Wire
Tickers SGEN
FDA Grants Accelerated Approval for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer
From Seagen Inc.
Via Business Wire
Tickers SGEN
Seagen to Present New Clinical and Preclinical Data From Broad Portfolio of Targeted Cancer Therapeutics at the 2023 AACR Annual Meeting
From Seagen Inc.
Via Business Wire
Tickers SGEN
Pfizer Invests $43 Billion to Battle Cancer
From Seagen Inc.
Via Business Wire
Tickers PFE SGEN
Astellas and Seagen Announce China’s National Medical Products Administration Accepts Biologics License Application for Enfortumab Vedotin in Certain Patients with Locally Advanced or Metastatic Urothelial Cancer
From Seagen Inc.
Via Business Wire
Tickers SGEN
Seagen to Present at the Cowen 43rd Annual Health Care Conference
From Seagen Inc.
Via Business Wire
Tickers SGEN
Seagen Reports Fourth Quarter and Full Year 2022 Financial Results
From Seagen Inc.
Via Business Wire
Tickers SGEN
Seagen to Highlight Research in Urothelial Cancer at the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium
From Seagen Inc.
Via Business Wire
Tickers SGEN
Seagen Announces FDA Accelerated Approval of TUKYSA® (tucatinib) in Combination with Trastuzumab for People with Previously Treated RAS Wild-Type, HER2-Positive Metastatic Colorectal Cancer
From Seagen Inc.
Via Business Wire
Tickers SGEN
Seagen to Host Conference Call and Webcast Discussion of Fourth Quarter and Full Year 2022 Financial Results on February 15, 2023
From Seagen Inc.
Via Business Wire
Tickers SGEN
Seagen to Present at the J.P. Morgan Healthcare Conference
From Seagen Inc.
Via Business Wire
Tickers SGEN
Seagen, Astellas and Merck Announce FDA Acceptance of sBLAs for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer
From Seagen Inc.
Via Business Wire
Tickers MRK SGEN
Seagen Announces Results from Phase 2 Clinical Trial of ADCETRIS® (brentuximab vedotin) with Novel Immunotherapy Combination in Patients with Advanced- and Early-Stage Classical Hodgkin Lymphoma
From Seagen Inc.
Via Business Wire
Tickers SGEN
Seagen to Highlight ADCETRIS® (brentuximab vedotin) Clinical Progress at the 2022 American Society of Hematology (ASH) Annual Meeting
From Seagen Inc.
Via Business Wire
Tickers SGEN
Seagen Announces U.S. FDA Approval of New Indication for ADCETRIS® (brentuximab vedotin) for Children with Previously Untreated High Risk Hodgkin Lymphoma
From Seagen Inc.
Via Business Wire
Tickers SGEN
Seagen to Highlight New Research from its Diverse Pipeline of Targeted Cancer Therapy Candidates at the Society for Immunotherapy of Cancer’s (SITC) Annual Meeting
From Seagen Inc.
Via Business Wire
Tickers SGEN
Seagen Appoints Sandra M. Swain, M.D., to Board of Directors
From Seagen Inc.
Via Business Wire
Tickers SGEN
Seagen Names David R. Epstein as Chief Executive Officer and Director
From Seagen Inc.
Via Business Wire
Tickers SGEN
Seagen Reports Third Quarter 2022 Financial Results
From Seagen Inc.
Via Business Wire
Tickers SGEN
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.